Literature DB >> 8878065

Effect of epinine on tension of human renal arteries.

R H Schwinger1, C Schulz, K Brixius, M Böhm, J Müller-Ehmsen, E Erdmann.   

Abstract

BACKGROUND: The present study aimed to characterize the effects of epinine, the active metabolite of ibopamine on tension development in human renal arteries. METHODS AND
RESULTS: Experiments were performed on isolated human renal arteries rings obtained during surgery due to kidney tumors (n = 12). Epinine concentration-dependently relaxed isolated precontracted (PGF2 alpha) human renal artery rings (P < 0.05) in the presence of phentolamine, as effectively (epinine -30 +/- 4 mN, dopamine -31 +/- 5 mN) and with the same potency as dopamine (epinine EC50 0.7 mumol/l (0.4-1.2 mumol/l), dopamine 0.5 mumol/l (0.2-1.7 mumol/l). This effect was antagonized by the specific D1-receptor-antagonist SCH 23390. Effective beta-adrenoceptor antagonistic concentrations of propranolol did not affect epinine-induced vasorelaxation. In the absence of alpha- and beta-adrenoceptor-antagonists the potency of epinine to contract renal artery rings was significantly higher compared to dopamine indicating a higher affinity of epinine to alpha-adrenoceptors.
CONCLUSION: The present study provides evidence for direct vasodilatory effects of epinine via activation of D1-receptors on human renal arteries.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878065     DOI: 10.1007/bf00171066

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

Review 1.  Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.

Authors:  L I Goldberg; Y Y Hsieh; L Resnekov
Journal:  Prog Cardiovasc Dis       Date:  1977 Jan-Feb       Impact factor: 8.194

Review 2.  Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure.

Authors:  O E Brodde
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

3.  Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart.

Authors:  J D Port; E M Gilbert; P Larrabee; P Mealey; K Volkman; R Ginsburg; R E Hershberger; J Murray; M R Bristow
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

4.  Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.

Authors:  A J Nichols; R R Ruffolo
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

5.  Lack of desensitization of alpha- and beta-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist.

Authors:  O E Brodde; I Klusmann; M Wojcik; A J Man in't Veld; F Boomsma; M C Michel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

7.  Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors:  S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

8.  Comparison of the cardiovascular actions of dopamine and epinine in the dog.

Authors:  H Itoh; J D Kohli; S I Rajfer; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

9.  Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).

Authors:  D J van Veldhuisen; A J Man in 't Veld; P H Dunselman; D J Lok; H J Dohmen; J C Poortermans; A J Withagen; W H Pasteuning; J Brouwer; K I Lie
Journal:  J Am Coll Cardiol       Date:  1993-11-15       Impact factor: 24.094

10.  Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure.

Authors:  C Missale; M Metra; S Sigala; M Memo; L Dei Cas; P F Spano
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

View more
  1 in total

1.  [Effect of changed extracellular K(+) and Mg(2+)-concentration on intracellular Ca(2+) homeostasis, contraction coupling and force-frequency relations in the human myocardium].

Authors:  R H Schwinger; K Frank; S Hoischen; J Müller-Ehmsen; K Brixius
Journal:  Herz       Date:  1997-06       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.